Christine Bellon - Mar 16, 2023 Form 3 Insider Report for Beam Therapeutics Inc. (BEAM)

Role
Chief Legal Officer
Signature
By: /s/ Christine Bellon
Stock symbol
BEAM
Transactions as of
Mar 16, 2023
Transactions value $
$0
Form type
3
Date filed
3/27/2023, 06:22 PM
Next filing
Mar 31, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BEAM Common Stock 58.4K Mar 16, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BEAM Stock Option (Right to Buy) Mar 16, 2023 Common Stock 24K $80.04 Direct F3, F4
holding BEAM Stock Option (Right to Buy) Mar 16, 2023 Common Stock 30K $69.21 Direct F5
holding BEAM Stock Option (Right to Buy) Mar 16, 2023 Common Stock 35K $43.45 Direct F6
holding BEAM Stock Option (Right to Buy) Mar 16, 2023 Common Stock 19.9K $7.22 Direct F7, F8
holding BEAM Stock Option (Right to Buy) Mar 16, 2023 Common Stock 19.4K $7.22 Direct F9, F10
holding BEAM Stock Option (Right to Buy) Mar 16, 2023 Common Stock 10K $110.92 Direct F11
holding BEAM Stock Option (Right to Buy) Mar 16, 2023 Common Stock 25K $39.11 Direct F12
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 9,375, 3,750, 15,000 and 12,500 restricted stock units ("RSUs") granted to the Reporting Person under the Issuer's 2019 Equity Incentive Plan on March 31, 2021, September 30, 2021, March 31, 2022 and December 30, 2022, respectively.
F2 Each RSU represents the contingent right to receive one share of the Issuer's common stock. The March 31, 2021, September 30, 2021 and March 31, 2022 RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with the Issuer through each vesting date. The December 30, 2022 RSUs vest in three substantially equal installments on each of the first three anniversaries of the grant date, subject to the Reporting Person's continued service with the Issuer through each vesting date. The March 31, 2021 RSUs grant was originally for 12,500 RSUs of which 3,125 RSUs have already vested. The September 30, 2021 RSUs grant was originally for 5,000 RSUs of which 1,250 RSUs have already vested.
F3 The option vests at a rate of 2.08% each month until the option is fully vested.
F4 The option grant was originally for options to purchase 25,000 shares of the Issuer's common stock of which 1,041 have already been exercised.
F5 The option vests at a rate of 2.08% each month until the option is fully vested.
F6 The option vests at a rate of 2.08% each month thereafter until the option is fully vested.
F7 The option vests as to 25% on the first anniversary of the vesting commencement date, May 16, 2020, and at a rate of 2.78% each month thereafter until the option is fully vested.
F8 The option grant was originally for options to purchase 100,350 shares of the Issuer's common stock of which 80,404 have already been exercised.
F9 The option vests as to 25% on the first anniversary of the vesting commencement date, May 17, 2020, and at a rate of 2.78% each month thereafter until the option is fully vested.
F10 The option grant was originally for options to purchase 42,704 shares of the Issuer's common stock of which 23,299 have already been exercised.
F11 The option vests at a rate of 2.08% each month thereafter until the option is fully vested.
F12 The option vests at a rate of 2.78% each month until the option is fully vested.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney